Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency (COVIT-D)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04403932 |
Recruitment Status :
Recruiting
First Posted : May 27, 2020
Last Update Posted : June 1, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Coronavirus Disease 2019 (COVID-19) |
Study Type : | Observational |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Cohort Study to Determine the Association Between Vitamin D Deficiency and Severity of the Disease in Patients With Coronarvirus Disease 2019 (COVID-19) |
Actual Study Start Date : | April 17, 2020 |
Estimated Primary Completion Date : | June 1, 2020 |
Estimated Study Completion Date : | July 1, 2020 |

- severe COVID-19 [ Time Frame: 17/04/2020 to 01/06/2020 ]death, admission to the intensive care unit, and/or a need for higher oxygen flow than that provided by nasal cannula

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- >18 years old
- symptoms suggestive of COVID-19
- positive reverse-transcriptase polymerase chain reaction or antibodies for SARS-CoV-2
Exclusion Criteria:
- Bacterial community acquired pneumonia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04403932
Spain | |
Hospital Clínico San Carlos | Recruiting |
Madrid, Spain, 28040 | |
Contact: Francisco J Martín, MD PhD 618746084 fjjms@hotmail.com |
Responsible Party: | Fernando Macaya, MD, Hospital San Carlos, Madrid |
ClinicalTrials.gov Identifier: | NCT04403932 |
Other Study ID Numbers: |
20/428-E_COVID |
First Posted: | May 27, 2020 Key Record Dates |
Last Update Posted: | June 1, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Coronavirus Disease 2019 (COVID-19) Vitamin D Deficiency Severe Acute Respiratory Syndrome Angiotensin Converting Enzyme 2 |
Coronavirus Infections Vitamin D Deficiency Coronaviridae Infections Nidovirales Infections RNA Virus Infections |
Virus Diseases Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders |